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Abstract
Hepatitis C virus (HCV) causes increased mortality and morbidity in kidney transplant patients. Interferon-based therapies are poorly tolerated 
and involve the risk of rejection. The new direct-acting antiviral drugs (DAAs) have revolutionized the treatment of HCV infection in transplant 
patients. This observational study evaluates changes in immunosuppressive therapy during treatment with DAA in renal transplant recipients.
In our transplant center, we selected seven HCV-positive patients at the time of transplantation , four men and three women, with an average 
age of 61 ± 7 years, in therapy with DAA. The dose and the blood levels of the immunosuppressive drugs were evaluated at the beginning and 
end of antiviral therapy, together with creatinine and proteinuria.
Viremia was negativized in all patients within the initial 8 weeks of therapy. Currently, the number of patients is too limited to perform a sta-
tistical analysis and obtain significant results. In one patient, the dose of Cyclosporine was lowered to 10 mg, while for the remaining patients it 
was not necessary to change the dose of immunosuppressive drugs.
DAAs give encouraging results in the eradication of HCV in renal transplant recipients, although they are associated with potential adverse 
drug interactions. The preliminary data of our study suggest that it is not necessary to change the dose of immunosuppressive drugs during 
therapy and that creatinine and proteinuria remain stationary. We will achieve more significant results in the future, adding more patients to our 
study. However, further randomized trials are necessary to confirm the safety of DAAs.
Monocentric experience of the use of DAAS in kidney transplant patients with HCV infection.
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Introduction
Before the introduction of new direct-acting antiviral drugs 
(DAAs), anti-hepatitis C virus (HCV) therapy was based on 
Interferon and Ribavirin, but these drugs were poorly used in 
kidney transplantation because of an increased risk of rejec-
tion and direct nephrotoxicity, respectively.
The use of DAAs has revolutionized the treatment of 
HCV infection, leading to a very effective clearance of viral 
load and expanding the population of potentially treatable 
patients.
There have been debates regarding the use of DAAs in 
kidney transplantation because of potential interactions 
with the immunosuppressive drugs.
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and the log rank test for survival analysis. All the tests were 
performed using SPSS software.
Results
We analyzed seven patients that were treated with a complete 
course of therapy of 12 weeks. Table 1 depicts the charac-
teristics of the patients. The virus genotype was 1b in four 
patients and 1a in the other three patients, as shown in 
Table 2. Viremia was cleared in all patients within 8 weeks 
from the start of therapy with DAAs.
Blood level of Cya or Fk remained substantially stable in 
all the patients except in one patient for whom it was nec-
essary to reduce the dose of Cya of 10 mg. No other dose 
adjustment was required in any other patient.
None of the parameters that we evaluated had a statisti-
cally significant variation, with the exception of ALT, which 
decreased from 38 ± 11,189 to 1500 ± 8025 (P-value: 0.02) after 
12 weeks of treatment with DAAs. Renal function remained 
stable throughout the course of the therapy (see Table 1).
None of the patients reported symptoms related to DAA 
side-effects like diarrhea, headache, weakness, or pruritus.
Discussion
Our study shows that DAAs are safe and effective in kid-
ney transplant recipients. Viremia was cleared in all treated 
patients, and none of the patients had to stop the course of 
therapy because of serious adverse effects or drug intoler-
ance. The use of DAAs had no influence on the parameters 
of renal function and the blood levels of immunosuppressive 
drugs except in one patient, but it is hard to ascertain whether 
this slight dose reduction (10 mg/daily) was needed because 
of any interaction between DAAs and Cya. This finding is 
Evidence from literature has demonstrated that an adjust-
ment in immunosuppressive medications was necessary in 
18% of kidney transplant patients treated with DAAs (1).
In this study, we evaluated retrospectively the safety and 
efficacy of DAAs in kidney transplant patients.
Methods
In this single-center, observational retrospective study, we 
selected all the patients that were treated with DAAS for 
HCV chronic infection from the cohort of kidney transplant 
patients on follow-up in our transplant center at the time of 
the analysis.
Treatment included the use of Daclatasvir 60 mg + Sofos-
buvir 400 mg in three patients, Sofosbuvir 600 mg + Vel-
patasvir 100 mg in two patients, and Ledipasvir 90 mg + 
Sofosbuvir 400 mg in two patients. The choice of the DAAS 
was made by the hepatologists according to their institu-
tion protocol. All patients were treated for 12 weeks. The 
 follow- up included a clinical and laboratory evaluation after 
the first, third, and the sixth months. We evaluated serum cre-
atinine, estimated glomerular filtration range (eGFR), blood 
urea nitrogen (BUN), 24-h proteinuria, viral load by means 
of HCV RNA, Alaline Amino Transferase (ALT), Aspartate 
Amino Transaminase (AST), total bilirubin, alkaline phos-
phatasis, gammaglutamiltransferasis (GGT), cyclosporine 
(Cya) or tacrolimus (Fk) trough levels, and the dose of Cya 
and Fk. Subjective side-effects (diarrhea, headache, weakness, 
pruritus) were evaluated by reviewing the medical records of 
the patients and interrogating the patients during the visit.
Statistical analysis: Comparisons were made using Stu-
dent’s t-test for paired samples and Wilcoxon’s rank-sum test 
when appropriate. The noncontinuous variables were com-
pared using the c2 test or Fisher’s exact test as appropriate 
Table 1. Patients characteristics.
Patient Sex Age HCV genotype Cause of ESKD DAAS
1 M 70 1b IgA GN Daclatasvir 60 mg + Sofosbuvir 400 mg 
2 F 62 1a HCV MPGN Daclatasvir 60 mg + Sofosbuvir 400 mg 
3 M 65 1b Unknown Daclatasvir 60 mg + Sofosbuvir 400 mg 
4 F 64 1b ADPKD Ledipasvir 90 mg + Sofosbuvir 400 mg 
5 F 61 1a ADPKD Ledipasvir 90 mg + Sofosbuvir 400 mg 
6 M 54 1b Nephroangiosclerosis Sofosbuvir 600 mg + Velpatasvir 100 mg
7 m 49 1b Extracapillary GN Sofosbuvir 600 mg + Velpatasvir 100 mg
IgA GN: IgA glomerulonephritis, HCV MPGN: HCV-related membranoproliferative glomerulonephritis, ADPKD: autoso-
mal dominant polycystic kidney disease, Extracapillary GN: Extracapillary glomerulonephritis, DAAS: direct-acting antiviral 
drugs, HCV: Hepatitis C virus, ESKD: End Stage Kidney Disease.
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In the MAGELLAN-2 trial, 20 kidney transplant recipients 
received glecaprevir-pibrentasvir, and all were cured  (7). 
Colombo et al. obtained SVR in 100% of the patients (1). 
Sawinsky et al. reported SVR in 100% of the patients, while 
45% required CNI adjustments; there were no episodes of 
rejection (8). Bhamidimarri et al. reported 25 cases of trans-
plantation of kidneys from hepatitis C-positive donors into 
HCV-infected recipients, followed by early initiation of 
direct-acting antiviral therapy. They observed SVR in 96% 
of patients, 52% required CNI adjustment, and four cases 
of antibody-mediated rejection on DAA treatment was 
reported (9). Lubetzky et al. reported SVR in 97% of cases, 
19% had worsening proteinuria during or shortly after ther-
apy with DAAs, 6% had eGFR decline below 20 mL/min, 
and 6% required CNI adjustment (10).
We did not observe any serious adverse events related to 
antiviral therapy to prove that DAAs have been well toler-
ated in all patients included in our study. Many other stud-
ies have confirmed the safety of DAAs in renal transplant 
recipients. In the trial by Colombo et al., adverse events 
experienced by more than 10% of those receiving Sofosbuvir- 
Ledipasvir were headache, weakness, and fatigue (1). In the 
 MAGELLAN-2 study, participants commonly reported 
fatigue (22%), headache (22%), nausea (12%), pruritus 
(12%), and diarrhea (10%) (7).
It is necessary to point out some limitations of our study; 
first of all, the number of patients enrolled is clearly too 
in contrast with the literature, since different studies showed 
pharmacological interactions between calcineurin inhibi-
tors and DAAs. A review by Chute et al. reported that on 
average, 97 of 287 patients (34%) in 10 retrospective series 
required calcineurin inhibitor dose adjustments during or 
shortly after DAA therapy (2). Colombo et al. randomized 
114 adult patients at least 6 months after kidney transplan-
tation to receive 12 or 24 weeks of Sofosbuvir + Ledipasvir 
400 mg/90 mg combination therapy. They observed that 18% 
of patients required adjustment in immunosuppressive med-
ications, in the absence of documented episodes of acute 
rejection (1). The study by Fernandez et al. reported that 
55% of patients required calcineurin inhibitors (CNI) dose 
adjustment, 16% experienced an increase in serum creati-
nine by more than 25% on DAAs therapy, observing three 
episodes of acute humoral rejection; however, adverse events 
specifically attributed to this regimen were not reported (3). 
Morales et al. enrolled 32 renal transplant recipients treated 
with Sofosbuvir- Ledipasvir, and 25% of them required CNI 
adjustment (4). Eisenberger et al. enrolled 15 renal trans-
plant recipients treated with Sofosbuvir- Ledipasvir, and 53% 
of them required CNI dose adjustment (5).
All the patients included in our study reached a sustained 
virologic response at 12 weeks (SRV 12), defined as an unde-
tectable HCV RNA 12 weeks after the completion of DAAs 
treatment (6). Likewise, several studies of DAAs used in kid-
ney transplant recipients reported remarkable success rates. 
AQ1
Table 2. Variation of the parameters at the beginning and after 12 weeks of therapy with Direct Acting Antivirals (DAA). 
Parameters are expressed as means and standard deviation.
Parameter T0 T12 P
Creatinine (mg/dL) 1.21 ± 0.2 1.32 ± 0.2 0.23
Azotemia (g/L) 0.57 ± 0.76 0.57 ± 0.076 0.46
Creatinine clearance (mL/min) 62.45 ± 16.0 57.55 ± 28.1 0.6
Alt (U/L) 38 ± 11,189 15.00 ± 8.0 0.02
Ast (U/L) 25 ± 6.5 20 ± 7.8 0.59
Bilirubin (mg/dL) 0.42 ± 0.19 0.41 ± 0.1 0.76
GGT (U/L) 59.40 ± 63.5 39.40 ± 25.5 0.39
PAL (U/L) 105.20 ± 64.5 97.00 ± 43.4 0.6
Proteinuria 24 h (g/24 h) 0.44 ± 0.3 0.43 ± 0.3 0.81
CyAlevels (ng/mL) 96.50 ± 4.9 79.00 ± 2.8 0.19
FK levels (ng/mL) 10.05 ± 1.9 8.85 ± 1.9 –
HCV RNA (Ui/mL) 2258703.23 ± 3458997.0 0 0.22
Hemoglobin (g/dL) 12,257 ± 1.1 12.47 ± 1.5 0.58
GGT: Gamma Glutamyl transferasis; PAL: alkaline phospatasis
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limited to process a valid statistical analysis and obtain sta-
tistically significant results. Furthermore, the study is retro-
spective and not controlled, and blood and urinary values 
were provided by different laboratories, located in different 
cities. Our cohort of patients is quite heterogeneous for age 
and transplant age.
Of note, we observed an alteration of GGT in two 
patients, of whom one had a history of gallbladder hydrops, 
episodes of cholangitis, and hepatic cysts infections, respon-
sible for cholestasis, and the other patient had an advanced 
HCV- related liver fibrosis. Moreover, in both patients, the 
alteration of this parameter was pre-existing to DAAs 
therapy, stable during therapy, and persistent after therapy 
discontinuation.
Conclusion
In our study, DAAs resulted in a safe and effective antiviral 
therapy in kidney graft recipients, and they are set to revo-
lutionize the natural history of HCV infection in transplant 
patients. Our study did not detect any significant variations 
in the blood levels of immunosuppressants, providing reas-
suring results, supported also by many other studies in the 
literature. Larger studies with longer follow-ups are needed 
to verify the efficacy of DAAs in transplant recipients in the 
long term, in particular to understand the risk of recurrence 
of viremia after years of treatment, and any link with the use 
of a particular immunosuppressant.
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